Nature Reviews Drug Discovery

Building on the momentum of N-of-1 base editor therapies for rare diseases

Katie Kingwell Aug 01, 2025 pp. 582-583 10.1038/d41573-025-00119-6

FDA new drug approvals in Q2 2025

Paul Verdin Aug 01, 2025 pp. 579-579 10.1038/d41573-025-00124-9

Lilly buys Verve and its in vivo gene editors for up to US$1.3 billion

Asher Mullard Aug 01, 2025 pp. 578-578 10.1038/d41573-025-00120-z

The US biosimilars market after one decade

Kritika Chaudhari, Duncan Emerton Aug 01, 2025 pp. 580-581 10.1038/d41573-025-00101-2

FDA approves twice-yearly capsid inhibitor for HIV prevention

Asher Mullard Aug 01, 2025 pp. 577-577 10.1038/d41573-025-00117-8

Dual-payload ADCs move into first oncology clinical trials

Asher Mullard Aug 01, 2025 pp. 573-576 10.1038/d41573-025-00121-y

Stealthy polymer attacks Gram-negative bacteria

Katie Kingwell Aug 01, 2025 pp. 587-587 10.1038/d41573-025-00118-7

FDA approves first factor XIIa inhibitor, for hereditary angioedema

Asher Mullard Aug 01, 2025 pp. 577-577 10.1038/d41573-025-00114-x

Enhancing CAR-T cell efficacy through IFN ablation

M. Teresa Villanueva Aug 01, 2025 pp. 587-587 10.1038/d41573-025-00115-w

A neonatal window for in vivo gene therapy in haematopoietic stem cells

Alex Eccleston Aug 01, 2025 pp. 586-586 10.1038/d41573-025-00116-9

Understanding semaglutide action in the brain

Sarah Crunkhorn Aug 01, 2025 pp. 588-588 10.1038/d41573-025-00112-z

Mosquito-targeted malaria control

Sarah Crunkhorn Aug 01, 2025 pp. 588-588 10.1038/d41573-025-00111-0

Inhibiting myosin in glioblastoma

Sarah Crunkhorn Aug 01, 2025 pp. 588-588 10.1038/d41573-025-00113-y

Base editing tackles trinucleotide repeat diseases

Sarah Crunkhorn Aug 01, 2025 pp. 588-588 10.1038/d41573-025-00110-1

Neurotensin receptor modulator safely tackles pain

Sarah Crunkhorn Aug 01, 2025 pp. 586-586 10.1038/d41573-025-00109-8

The landscape for radioligand therapies in oncology

Jerrick To, Rachel Magid, Jon Cleland et al. Aug 01, 2025 pp. 584-585 10.1038/d41573-025-00096-w

GLP-1-based therapies for diabetes, obesity and beyond

Daniel J. Drucker Aug 01, 2025 pp. 631-650 10.1038/s41573-025-01183-8

The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation

Carolina M. Polonio, Kimberly A. McHale, David H. Sherr et al. Aug 01, 2025 pp. 610-630 10.1038/s41573-025-01172-x

Biomarker-guided decision making in clinical drug development for neurodegenerative disorders

Jeffrey L. Cummings, Charlotte E. Teunissen, Brian K. Fiske et al. Aug 01, 2025 pp. 589-609 10.1038/s41573-025-01165-w

New approach methodologies: EU regulatory horizons

Mariana Edwards, Oriane Blanquie, Orla Moriarty et al. Aug 01, 2025 pp. 571-572 10.1038/d41573-025-00053-7